25-hydroxyvitamin D 3 suppresses hepatitis C virus production

Hepatology

Volumn 56, Issue 4, 2012, Pages 1231-1239

  Matsumura, Takuya ^a,b   Kato, Takanobu ^b   Sugiyama, Nao ^b   Tasaka Fujita, Megumi ^b   Murayama, Asako ^b   Masaki, Takahiro ^b   Wakita, Takaji ^b   Imawari, Michio ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CD81 ANTIGEN; COLECALCIFEROL; NONSTRUCTURAL PROTEIN 3; VIRUS ANTIGEN; VITAMIN D; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TITRATION; VITAMIN SUPPLEMENTATION; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; EPIDEMIOLOGY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIVER CELL; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ANTIVIRAL AGENTS; CALCIFEDIOL; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84867162487     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25763     Document Type: Article

References (34)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
2. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. HEPATOLOGY 2002; 36: S1-S2.
3. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
4. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. HEPATOLOGY 2006; 43: S207-S220.
5. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 43-50.
6. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-5190.
7. Imawari M, Kida K, Goodman DS. The transport of vitamin D and its 25-hydroxy metabolite in human plasma. Isolation and partial characterization of vitamin D and 25-hydroxyvitamin D binding protein. J Clin Invest 1976; 58: 514-523.
8. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-261.
9. VanAmerongen BM, Dijkstra CD, Lips P, Polman CH. Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr 2004; 58: 1095-1109.
10. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92: 39-48.
11. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985; 40: 187-190.
12. Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 1997; 349: 1801-1804.
13. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.
14. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 2007; 81: 5036-5045.
15. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
16. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999; 116: 636-642.
17. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: 1802-1808.
18. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997; 44: 1299-1305.
19. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
20. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278: 41624-41630.
21. Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 2005; 43: 5679-5684.
22. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006; 1: 2334-2339.
23. Kato T, Choi Y, Elmowalid G, Sapp RK, Barth H, Furusaka A, et al. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. HEPATOLOGY 2008; 48: 732-740.
24. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-243.
25. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004; 26: 21-28.
26. Liu PT, Modlin RL. Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 2008; 20: 371-376.
27. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. HEPATOLOGY 2010; 51: 1158-1167.
28. Lou YR, Molnar F, Perakyla M, Qiao S, Kalueff AV, St-Arnaud R, et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 2010; 118: 162-170.
29. Jones DM, Atoom AM, Zhang X, Kottilil S, Russell RS. A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus. J Virol 2011; 85: 12351-12361.
30. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148-154.
31. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bucker A, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008; 15: 790-796.
32. Imawari M, Akanuma Y, Itakura H, Muto Y, Kosaka K, Goodman DS. The effects of diseases of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. J Lab Clin Med 1979; 93: 171-180.
33. Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 1989; 35: 225-234.
34. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, et al. Vitamin-D: an innate antiviral agent suppressing Hepatitis C virus in human hepatocytes. HEPATOLOGY 2011; 54: 1570-1579.